Skip to main content
SpringerLink
Log in

Evaluation of Capacity-Limited First-Pass Effect through Liver by Three-Points Sampling in Portal and Hepatic Veins and Systemic Artery

  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

Abstract

Purpose. The three-points method was newly developed by sampling the portal and hepatic veins and systemic artery. A model of hepatic local disposition with the Michaelis-Menten elimination was proposed to explain the concentration dependency of the hepatic recovery ratio (F H).

Methods. 5-fluorouracil (5-FU) was selected as a model drug. 5-FU was administered orally 90 min after its intraarterial dose. Blood specimens in both femoral artery and hepatic vein were sampled after intraarterial dose, and blood specimens in both femoral artery and portal vein were taken after oral administration.

Results. It was shown that F H increased with an increase in the input drug concentration into the liver. The mean absorption time (MAT) estimated by nonlinear analysis agreed with the mean local absorption time (t a) whereas MAT by linear analysis was significantly smaller than t a.

Conclusions. The three-points method was newly developed, and the proposed nonlinear model explained well the capacity-limited elimination of 5-FU through the liver. MAT by the nonlinear analysis was in good agreement with t a.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  1. H. Yasui, K. Yamaoka, T. Fukuyama, and T. Nakagawa. Effect of liver intoxication by carbon tetrachloride on hepatic local disposition of oxacillin using moment characteristics as index. Drug Metab. Dispos. 23:779–785 (1995).

    Google Scholar 

  2. W. Tang, R. A. Stearns, G. Y. Kwei, S. A. Iliff, R.R. Miller, M.A. Egan, N.X. Yu, D.C. Dean, S. Kumar, M. Shou, J.H. Lin, and T. A. Baillie. Interaction of diclofenac and quinidine in monkeys: Simulation of diclofenac metabolism. J. Pharmacol. Exp. Ther. 291:1068–1074 (1999).

    Google Scholar 

  3. T. Mushiroda, R. Douya, E. Takahara, and O. Nagata. The involvement of flavin-containing monooxygenase but not CYP3A4 in metabolism of itopride hydrochloride, a gastroprokinetic agent: Comparison with cisapride and mosapride citrate. Drug Metab. Dispos. 28:1231–1237 (2000).

    Google Scholar 

  4. E. Arlander, G. Ekstrom, C. Alm, J. A. Carrillo, M. Bielenstein, Y. Bottiger, L. Bertilsson, and L. L. Gustafsson. Metabolism of ropivacaine in humans is mediated by CYP1A2 and to a minor extent by CYP3A4: An interaction study with fluvoxamine and ketoconazole as in vivo inhibitors. Clin. Pharmacol. Ther. 64:484–491 (1998).

    Google Scholar 

  5. H. Nakayama, T. Kinouchi, K. Kataoka, S. Akimoto, Y. Matsuda, and Y. Ohnishi. Intestinal anaerobic bacteria hydrolyse sorivudine, producing the high blood concentration of 5-(E)-(2-bromovinyl)uracil that increases the level and toxicity of 5-fluorouracil. Pharmacogenetics 7:35–43 (1997).

    Google Scholar 

  6. T. Watabe, H. Okuda, and K. Ogura. Lethal drug interactions of the new antiviral sorivudine, with anticancer prodrugs of 5-fluorouracil. Yakugaku Zasshi 117:910–921 (1997).

    Google Scholar 

  7. H. Okuda, T. Nishiyama, Y Ogura, S. Nagayama, K. Ikeda, S. Yamaguchi, Y. Nakamura, K. Kawaguchi, and T. Watabe. Lethal drug interactions of sorivudine, a new antiviral drug, with oral 5-fluorouracil prodrugs. Drug Metab. Dispos. 25:270–273 (1997).

    Google Scholar 

  8. T. Yamada, K. Niinuma, M. Lemaire, T. Terasaki, and Y. Sugiyama. Carrier-mediated hepatic uptake of the cationic cyclopeptide, octretide, in rats comparison between in vivo and in vitro. Drug Metab. Dispos. 25:536–543 (1997).

    Google Scholar 

  9. R. M. Bremnes, L. Slordal, E. Wist, and J. Aarbakke. Dosedependent pharmacokinetics of methotrexate and 7-hydroxymethotrexate in the rat in vivo. Cancer Res. 49:6359–6364 (1989).

    Google Scholar 

  10. R. F. Frye, A. Adedoyin, K. Mauro, G. R. Matzke, and R. A. Branch Use of chlorzoxazone as an in vivo probe of cytochrome P450 2E1: Choice of dose and phenotypic trait measure. J. Clin. Pharmacol. 38:82–89 (1998).

    Google Scholar 

  11. K. Tabata, K. Yamaoka, T. Fukuyama, and T. Nakagawa. Evaluation of intestinal absorption into the portal system in enterohepatic circulation by measuring the difference in portal-venous blood concentrations of diclofenac. Pharm. Res. 12:880–883 (1995).

    Google Scholar 

  12. D. J. Hoffman, T. Seifert, A. Borre, and H. N. Nellans. Method to estimate the rate and extent of intestinal absorption in conscious rats using an absorption probe and portal blood sampling. Pharm. Res. 12:889–894 (1995).

    Google Scholar 

  13. Y. Fujieda, K. Yamaoka, T. Ito, and T. Nakagawa. Local absorption kinetics of levofloxacin from intestinal tract into portal vein in conscious rat using portal-venous concentration difference. Pharm. Res. 13:1201–1204 (1996).

    Google Scholar 

  14. Y. Sawai, K. Yamaoka, A. Takemura, and T. Nakagawa. Moment analysis of intestinal first-pass metabolism by portal-systemic concentration difference in single conscious rat using 5'-deoxy-5-fluorouracil as model drug system. J. Pharm. Sci. 86:1269–1272 (1997).

    Google Scholar 

  15. T. Ito, K. Yamaoka, and T. Nakagawa. Short-period doubledosing for simultaneous evaluation of intestinal absorption and hepatic disposition in a single conscious rat using cephalexin as test drug. J. Pharm. Pharmacol. 49:1189–1194 (1997).

    Google Scholar 

  16. S. Ueda, K. Yamaoka, T. Nakagawa. Effect of pentobarbital anesthesia on intestinal absorption and hepatic first-pass metabolism of oxacillin in rats, evaluated by portal-systemic concentration difference. J. Pharm. Pharmacol. 51:585–589 (1998).

    Google Scholar 

  17. Y. Sawai, K. Yamaoka, T Ito, and T. Nakagawa. Simultaneous evaluation of intestinal absorption and hepatic extraction of 5-fluorouracil using portal-systemic concentration difference by short-period double dosing in a single conscious rat. Biol. Pharm. Bull. 20:1313–1316 (1997).

    Google Scholar 

  18. M. Higashimori, K. Yamaoka, and T. Nakagawa. Dose-dependency in local disposition of 5-fluorouracil under non-steadystate condition in rat liver. J. Pharm. Sci. 89:100–107 (2000).

    Google Scholar 

  19. B. E. Harris, R. L. Song, S. J. Soong, and R.B. Diasio. Circadian variation of 5-fluorouracil catabolism in isolated perfused rat liver. Cancer Res. 49:6610–6614 (1989).

    Google Scholar 

  20. J. Nishigaki, S. Suzuki, J. Yui, and A. Shigematsu. Distribution volume of three 99mTc-labeled compounds in the rat liver with time after intraportal and intravenous injections. Biol. Pharm. Bull. 18:1705–1709 (1995).

    Google Scholar 

  21. J. Nishigaki, Y. Suzuki, and A. Shigematsu. A novel method for measuring the hepatic first-pass effect and metabolic rate of L-3,4-dihydroxyphenylalanine (DOPA), diazepam and inulin in rat liver. Biol. Pharm. Bull. 21:735–740 (1998).

    Google Scholar 

  22. K. Yamaoka, T. Nakagawa, and T. Uno. Statistical moments in pharmacokinetics. J. Pharmacokinet. Biopharm. 6:547–558 (1978).

    Google Scholar 

  23. K. B. Bischoff, R. L. Dedrick, D. S. Zaharko, and J. A. Longstreth. Methotrexate pharmacokinetics. J. Pharm. Sci. 60:1128–1133 (1971).

    Google Scholar 

  24. K. Yamaoka, Y. Tanigawara, T. Nakagawa, and T. Uno. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmaco. Dyn. 4:879–885 (1981).

    Google Scholar 

  25. M. Weiss and W. Forster. Pharmacokinetic model based on circulatory transport. Eur. J. Clin. Pharmacol. 16:287–293 (1979).

    Google Scholar 

  26. M. Weiss. Definition of pharmacokinetic parameters: Influence of the sampling site. J. Pharmacokinet. Biopharm. 11:63–75 (1983).

    Google Scholar 

  27. K.C. Kwan. Oral bioavailability and first-pass effects. Drug Metab. Dispos. 25:1329–1336 (1997).

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Graduate School of Pharmaceutical Sciences, Kyoto University, Yoshida Shimoadachi-cho, Sakyo-ku, Kyoto, 606-8501, Japan

    Shinya Ueda, Kiyoshi Yamaoka & Terumichi Nakagawa

  2. Institute of Whole Body Metabolism, Shiroi, Chiba, 270-1407, Japan

    Jyoji Yui & Akio Shigematsu

Authors
  1. Shinya Ueda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kiyoshi Yamaoka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jyoji Yui
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Akio Shigematsu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Terumichi Nakagawa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kiyoshi Yamaoka.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ueda, S., Yamaoka, K., Yui, J. et al. Evaluation of Capacity-Limited First-Pass Effect through Liver by Three-Points Sampling in Portal and Hepatic Veins and Systemic Artery. Pharm Res 19, 852–857 (2002). https://doi.org/10.1023/A:1016165101921

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1016165101921

Search

Navigation